Castiglione Vincenzo, Vergaro Giuseppe, Aimo Alberto, Prontera Concetta, Musetti Veronica, Masotti Silvia, Battaglia Debora, Di Cecco Pietro, Emdin Michele, Passino Claudio
Istituto di Scienze della Vita, Scuola Superiore Sant'Anna, Pisa.
Istituto di Scienze della Vita, Scuola Superiore Sant'Anna, Pisa - Fondazione Toscana Gabriele Monasterio, Pisa.
G Ital Cardiol (Rome). 2021 Apr;22(4):292-300. doi: 10.1714/3574.35575.
Heart failure (HF) is the final common pathway of many cardiovascular diseases and is associated with increased morbidity and mortality. Natural history of HF patients can be improved when early diagnosis is achieved, and a timely treatment is initiated. Circulating biomarkers, reflecting pathophysiological pathways involved in HF development and progression, help clinicians diagnose and manage patients with HF. Natriuretic peptides are cardioprotective hormones released by cardiomyocytes in response to pressure/volume overload. B-type natriuretic peptides, namely B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide, have been widely validated as tools for diagnosis and risk stratification of HF, and their use appears promising also for screening the population at risk and as a guide for preventive measures halting progression towards HF. Conversely, there is conflicting evidence regarding their role as a guidance for HF therapy.
心力衰竭（HF）是许多心血管疾病的最终共同通路，与发病率和死亡率的增加相关。当实现早期诊断并开始及时治疗时，HF患者的自然病程可以得到改善。反映HF发生和进展所涉及的病理生理途径的循环生物标志物有助于临床医生诊断和管理HF患者。利钠肽是心肌细胞在压力/容量超负荷时释放的心脏保护激素。B型利钠肽，即B型利钠肽和N末端前B型利钠肽，已被广泛验证为HF诊断和风险分层的工具，它们在筛查高危人群以及作为阻止向HF进展的预防措施指南方面似乎也很有前景。相反，关于它们作为HF治疗指南的作用存在相互矛盾的证据。
